Inhibition of RAS/RAF/MEK/ERK has achieved remarkable success in some cancers but has so far been ineffective in others, including breast cancer, and new generations of inhibitors are under development [43,44,45,46,47]. This evidence concerns the gene MAP2K7 and breast carcinoma.